XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication
– XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea’s National Health Insurance Service (NHIS)…
Browsing Tag